Observed Signal · Nov 19, 2025 · Funding · Source: AdExchanger · Impact: 2/5 · Sentiment: Positive
Havas Invests in AI Research Platform, Enhances Client Insights
Vurvey Labs, an AI-powered research platform, announced $8.5 million in Series A funding led by Havas, which also becomes a customer and partner. The deal ties Vurvey to Havas through client recommendations, board representation, and integration across Havas' health and creative divisions. Vurvey's core offering is a 'people model'—a large-scale AI model trained on millions of customer interviews to generate AI agents and populations reflecting diverse personalities and behaviors. Training relies on self-recorded video interviews rather than text Q&As, capturing emotions and mannerisms. The company also uses first- and third-party data from social platforms and a brand's internal data. Havas Health uses Vurvey to create synthetic doctor personas for pharma clients, helping understand reactions to dosing approaches and accelerating scenario testing from weeks to minutes. The approach aims to preserve human insight while scaling interviewing across populations, per founder Chad Reynolds and Havas executives.
Mid-level funding and partnership in AI research platform within the advertising industry
Track Vivendi Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Vurvey Labs raised $8.5 million in Series A funding led by Havas.
- Havas becomes lead investor and customer; partnership includes client recommendations, board representation, and integration across Havas' health and creative divisions.
- Vurvey offers a 'people model' AI platform trained on millions of customer interviews to generate AI agents and diverse personas.
- Training uses self-recorded video interviews to capture emotions and mannerisms; data sources include first- and third-party data from social platforms and a brand's internal data.
- Havas Health uses Vurvey to create synthetic doctor personas for pharma clients, speeding up scenario testing from weeks to minutes.
Connected Companies & Entities
1 Entity mappedRelated Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Conveo Raises $50M for AI Consumer Intelligence
Belgian startup Conveo has secured $50 million in Series A funding to expand into the US and develop its AI-powered consumer intelligence platform. The round was led by DST Global Partners, Balderton Capital, Visionaries, 6 Degrees Capital, and Y Combinator, bringing total funding to $55.8 million. Conveo's technology conducts AI-driven video interviews with consumers to gather qualitative insights at scale, supporting methods like MaxDiff, price sensitivity, and diary studies. The platform is used by over 400 enterprises, including 50 Fortune 500 companies and clients such as Google, Unilever, AB InBev, and Canva. The funding will also support the rollout of StoryLines, a new product that enables continuous research on strategically important topics, building an evolving knowledge base for product, marketing, and strategy teams.
AI Benchmarking Startup Vals Raises $40M Series A
Vals, a startup founded in 2024, aims to become the gold standard for AI benchmarking. The company has raised a $40 million Series A led by Andreessen Horowitz, following a seed round led by 8VC and Bloomberg Beta. Vals differentiates itself by keeping its test materials private to prevent companies from gaming the system, and by evaluating models on industry-specific tasks in law, finance, and coding, as well as emerging areas like cybersecurity and biosecurity. The company's revenue is eight times what it was last year, and its team has grown from eight to 25 employees. Vals also launched a program to provide model evaluations to federal agencies. Founder Rayan Krishnan believes that as AI companies go public, rigorous benchmarking will become essential for public trust and corporate governance.
Vivodyne builds robotic labs to improve AI drug discovery
Vivodyne, a biotech startup spun out of the University of Pennsylvania, says the AI drug‑discovery field lacks the causal human biological data needed to train useful models and has built HIVE — modular robotic labs that grow human tissues, autonomously dose and monitor them, and generate longitudinal experimental data. The company claims its tissues achieve high concordance with human trial outcomes (e.g., liver 94%, airway 96%, bone marrow 100% on tested chemotherapies), has raised just under $80 million across two rounds led by Khosla Ventures, and last week opened what it calls the world’s largest “human data center” near San Francisco to scale throughput and feed AI research. Vivodyne positions its dataset as a way to enable causal, reinforcement‑learning style models for more predictive human biology and combination‑therapy design.
Track Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.